2-pyridone compounds
The invention provides compounds of formula wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
1. The compound 3-(5-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamido)-N,N,N-trimethylpropan-1-aminium Y;
wherein Y represents a pharmaceutically acceptable anion.
2. The compound as defined in claim 1 which is 3-(5-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamido)-N,N,N-trimethylpropan-1-aminium benzenesulfonate.
3. A pharmaceutical composition comprising a compound as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
4. The compound as defined in claim 2 which is 3-(5-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamido)-N,N,N-trimethylpropan-1-aminium benzenesulfonate Form A, characterized in that said Form A has an X-ray powder diffraction pattern with specific peaks at 4.3, 11.5 and 23.1°2θ when measured using CuKα1 radiation.
5. The compound as defined in claim 2 which is 3-(5-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamido)-N,N,N-trimethylpropan-1-aminium benzenesulfonate Form B, characterized in that said Form B has an X-ray powder diffraction pattern with specific peaks at 5.8, 7.5 and 17.2°2θ when measured using CuKα1 radiation.